Alumis (NASDAQ:ALMS) Azioni

ALUMIS INC

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Analisi dei segnali di allarme nel settore sanitario: cosa rivela l&#39;indicatore tecnico chiave per gli investitori. È il momento di agire?

3 titoli del settore sanitario che potrebbero crollare nel secondo trimestre

Alumis Inc

As previously reported on January 13, 2025, Edible Garden AG Incorporated (the "Company") announced its entry into a non-binding letter of intent (the "LOI") to purchase the outstanding share capital of Narayan d.o.o. and its subsidiaries. Upon further evaluation, the Company decided not to proceed with the transaction contemplated under the LOI and negotiations under the LOI have ceased.

Contracts

EDBL

Edible Garden Terminates Proposed Acquisition Of Narayan d.o.o. And Its Subsidiaries

WIIM

SPWH

Sportsman's Warehouse shares are trading lower after the company reported worse-than-expected Q1 financial results.

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) raises FY2025 sales outlook from $1.16 billion-$1.17 billion to $1.18 billion-$1.19 billion vs $1.17 billion estimate.

Guidance

GWRE

Guidewire Software Raises FY2025 Sales Guidance from $1.16B-$1.17B to $1.18B-$1.19B vs $1.17B Est

This prospectus relates to the sale from time to time in one or more offerings of up to $400,000,000 of shares of our common stock, par value $0.0001 ("Common Stock"); shares of our preferred stock, par value $0.0001 ("Preferred Stock"), which we may issue in one or more series or classes; debt securities, which we may issue in one or more series; warrants to purchase our Common Stock, Preferred Stock or debt securities; and units (collectively referred to as the "securities").
We will provide the specific terms of any securities to be offered in one or more supplements to this prospectus. The prospectus supplements may also add, update or change information contained in this prospectus. This prospectus may not be used to offer and sell securities unless accompanied by a prospectus supplement.

Offerings

QBTS

D-Wave Quantum Files Shelf Registration For Potential Sale Of Up To $400M In Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In One Or More Offerings

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) sees Q4 sales of $332.000 million-$340.000 million vs $299.63 million analyst estimate.

Guidewire Software Sees Q4 Sales $332.000M-$340.000M vs $299.63M Est

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.61 by 44.26 percent. This is a 238.46 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $293.51 million which missed the analyst consensus estimate of $332.05 million by 11.61 percent. This is a 21.95 percent increase over sales of $240.68 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Guidewire Software Q3 Adj. EPS $0.88 Beats $0.61 Estimate, Sales $293.51M Miss $332.05M Estimate

RIME

Algorhythm Holdings shares are trading higher after the company announced its subsidiary won four new customer contracts and four new contract expansions.

Management

CABO

Cable One Announces That Julia M. Laulis, Chair Of Board Of Directors ,President, And CEO, Will Retire By December 31, 2025, Or At The Appointment Of Her Successor

Chicago Federal Reserve President Austan Goolsbee warned Tuesday that April&#8217;s softer inflation reading may be misleading, calling it possibly the "last vestige" of pre-tariff pricing, with more substantial upward pressure likely to <a href="https://www.benzinga.com/topic/inflation">appear in the coming months.</a>
Speaking during a moderated Q&amp;A at the Corridor Business Journal's 2025 Mid-Year Economic Review in Cedar Rapids, Iowa, Goolsbee emphasized that inflation data has so far shown "surprisingly little direct impact" from tariffs. But he cautioned that this may not last.
"If it's going to affect prices in a significant way, you would expect there's a one-month lag," Goolsbee said. "So that one would start showing up very soon."
<h3 class="wp-block-heading">Inflation Snapshot Misleading?</h3>
April's personal consumption expenditures (PCE) price index showed a 2.1% year-over-year increase—close to the Fed&#8217;s 2% target. 
Yet, Goolsbee said that number is backward-looking and likely underrepresents coming inflationary dynamics.
"What matters is what will the inflation rate be that's coming in."
He added, "We've had a couple of solid reports, inflation looks good. But these were the last reports before the tariffs."
Goldman Sachs echoed Goolsbee&#8217;s concerns in its latest inflation monitor. In a note shared Tuesday, the bank&#8217;s economist Jessica Rindels said the effect of new tariffs was modest in April, but the pressure is starting to surface.
"We expect tariffs to raise the effective tariff rate by 13 percentage points," Rindels said, projecting core PCE inflation will climb to 3.6% year-over-year by December 2025. Core CPI is forecast to hit 3.5%, up from April's 2.8%.
Most of that surge will likely come from goods categories highly dependent on imports, such as electronics, autos, and apparel. Meanwhile, services inflation—especially outside of housing—is expected to remain subdued for now.
<h3 class="wp-block-heading">Are Tariffs Truly Transitory?</h3>
Goolsbee raised doubts over the theoretical assumption that tariff-induced inflation is short-lived.
"In theory, if you put in a 10% tariff, you'd have 10% inflation for one year. But ‘transitory' is a bad word," he said, referencing the Fed's earlier misjudgment of COVID-era inflation. "I'm a little wary that the tariffs will have a transitory impact."
He described how business leaders in his district—home to the highest concentration of tariff-exposed states—have begun implementing price hikes in real-time.
"Last night at dinner with some CEOs here in Cedar Rapids, they described that in some cases, they just added a column to the spreadsheet—the tariff price," he said. "That implies a 100% pass-through."
<h3 class="wp-block-heading">Chicago Fed District Faces Disproportionate Exposure</h3>
Goolsbee highlighted that four of the seven most tariff-sensitive states—Iowa, Michigan, Indiana and Wisconsin—are in the Chicago Fed's jurisdiction. Those economies rely heavily on imported inputs and exports, especially in manufacturing and agriculture.
"There&#8217;s a lot of domestic production that's going to suffer," he said. "We'll have to figure out how to deal with that."
Despite his caution, Goolsbee still sees room for optimism on interest rates.
"I still think underneath all the tariff dirt in the air, rates can come down over 12–18 months," he said.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45724821/trumps-manufacturing-narrative-weakens-as-may-data-shows-sharper-contraction-stubborn-inflation">Trump&#8217;s Manufacturing Narrative Weakens As May Data Shows Sharper Contraction, Stubborn Inflation</a></li>
</ul>
 Photo: RozenskiP / Shutterstock.com

Econ #s

Federal Reserve

April Inflation Print Was The 'Last Vestige' Of Pre-Tariff Impact, Fed's Goolsbee Says

Acquisition Advances Permian Basin Growth Strategy
TULSA, Okla., June 3, 2025 /PRNewswire/ -- ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) today announced the acquisition of the remaining 49.9% interest in Delaware G&amp;P LLC (Delaware Basin JV) from NGP XI Midstream Holdings, L.L.C. for $940 million, consisting of $530 million in cash and $410 million in ONEOK common stock. &nbsp;
Delaware Basin JV owns natural gas gathering and processing facilities in the Delaware Basin in West Texas and New Mexico, with a total processing capacity of more than 700 million cubic feet per day. Following the close of the transaction on May 28, 2025, ONEOK became the sole owner of Delaware Basin JV.

ONEOK Acquires Remaining 49.9% Stake In Delaware Basin JV For $940M In Cash And Stock

ANAB

AnaptysBio shares are trading higher after the company announced Rosnilimab data from its six-month Phase 2b trial for rheumatoid arthritis (RA).

BJDX

Bluejay Diagnostics Plans 510(k) Submission For Symphony IL-6 Test In Q4 2027, Aiming For FDA Clearance By 2028

CREV

Carbon Revolution Receives Letter Of Non-Compliance From Nasdaq

CYCC

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.informatica.com&amp;esheet=54263387&amp;newsitemid=20250603208097&amp;lan=en-US&amp;anchor=Informatica&amp;index=1&amp;md5=e04bf37c13c32d20ebae0c20afad90af">Informatica</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>), a leader in enterprise AI-powered cloud data management, today announced new product innovations at Snowflake Summit, Snowflake's annual user conference, including expansion of its support for Apache Iceberg&#x2122;. These updates help joint customers use both companies' Generative AI (GenAI) technologies to build reliable, enterprise-level AI applications.
New Informatica Intelligent Data Management Cloud Application Integration Capabilities for Snowflake Cortex AI (now Generally Available globally):
<ul>
<li>New Cortex AI Connectivity: New connectors for Cortex AI, Cortex Search, Cortex Analyst and Cortex Agents</li>
<li>Simplified RAG and Agent Use Case Development: Simplify GenAI application creation for data professionals with no-code development and deployment with Snowflake Cortex AI</li>
</ul>
Informatica is enhancing its Open Table Connector (Apache Iceberg) to support Apache Polaris:
<ul>
<li>New Apache Iceberg Open Table Connector for Snowflake with support for Snowflake Apache Polaris(Private Preview): Informatica Cloud Data Integration's no-code/low-code data pipelines can now load data into Snowflake from over 300 sources using the Iceberg table format. All tables are automatically registered in Snowflake Apache Polaris, enabling seamless interoperability across Snowflake and other query engines (Planned release in July 2025).</li>
</ul>
Informatica Master Data Management Extension for Snowflake:
Informatica is launching its Master Data Management (MDM) SaaS Extension for the Snowflake AI Data Cloud, allowing customers to consolidate master and transaction data across multiple sources. The seamless integration between Informatica MDM and the Snowflake platform enables customers to easily load their trusted master data assets from Informatica's MDM SaaS including customer, supplier, product, patient, provider and other domains directly into the Snowflake AI Data Cloud. The integration brings together data from disparate domains, so data practitioners can power their analytics and AI use cases.
"Informatica continues to be at the forefront of Generative AI and Apache Iceberg innovation with Snowflake enabling our joint customers to build for the future with a trusted, AI-ready data foundation," said Rik Tamm-Daniels, Group Vice President of Strategic Ecosystems and Technology at Informatica. "Today's announcement underscores our relentless commitment to innovating and leading with Snowflake to deliver greater value for customers through deep product roadmap and partnership alignment."
"Informatica's Intelligent Data Management Cloud and Generative AI blueprint for Cortex AI provide a rich foundation of trusted data and metadata intelligence that has enabled us to accelerate innovation with Cortex Analyst and deliver GenAI experiences for our end users leveraging Snowflake data," said Moli Thomas, Senior Director of Enterprise Data and Analytics at HMH Education Company.
"Snowflake and Informatica continue to collaborate and innovate across product development and engineering to support enterprise customers," said Saptarshi Mukherjee, Director of Product, Data Engineering at Snowflake. "Informatica's expanded capabilities with the Cortex AI platform and private preview of its support for Snowflake Apache Polaris showcase our shared commitment to deliver an enhanced and seamless experience for enterprise customers using Snowflake to power their AI initiatives."

General

INFA

SNOW

Informatica Deepens Snowflake Partnership to Deliver Trusted, AI-Ready Data Via Polaris and Cortex AI

Biotech

TELA

TELA Bio Announces European Commercial Launch Of OviTex Inguinal Reinforced Tissue Matrix

Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) has outperformed the market over the past 20 years by 4.82% on an annualized basis producing an average annual return of 13.16%. Currently, Norfolk Southern has a market capitalization of $55.91 billion. 
Buying $1000 In NSC: If an investor had bought $1000 of NSC stock 20 years ago, it would be worth $11,801.08 today based on a price of $247.98 for NSC at the time of writing.
<h3>Norfolk Southern's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748981739_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

NSPR

InspireMD Appoints Michael Lawless As CFO, Effective June 30, 2025

HealthEquity shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and raised its FY26 guidance.

BASE

Couchbase Q1 Adj. EPS $(0.06) Misses $(0.05) Estimate, Sales $56.52M Beat $56.47M Estimate

Press Releases

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Stockholders Approve Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Completes Merger with ACELYRIN

Health Care

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Comments

Alumis

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO